胃复方对胃癌SGC-7901细胞株增殖及PPARγ基因活性的影响

发布时间：2017-12-31 03:09

本文关键词：胃复方对胃癌SGC-7901细胞株增殖及PPARγ基因活性的影响　出处：《湖南中医药大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的:通过观察胃复方含药血浆对胃癌SGC-7901细胞株增殖及对PPARγ(过氧化物酶增殖激活受体γ)的影响,对胃复方含药血浆影响胃癌细胞增殖可能机制进行探讨。方法:以胃复方含药血浆(终浓度为10%)空白组、低剂量组、中剂量组、高剂量组作用于胃复方SGC-7901细胞株,24h、48h、72h后分别用CCK-8法检测增殖抑制率。不同浓度的胃复方含药血浆作用胃癌SGC-7901细胞株后48h,以荧光定量法(q PCR)检测PPARγ在胃癌SGC-7901细胞株中的表达。结果:低剂量胃复方含药血浆的IC_(50)为11.1%±2.0%,中剂量胃复方含药血浆的IC_(50)为13.5%±3.1%,高剂量胃复方含药血浆IC_(50)为12.3%±1.5%。各含药血浆IC_(50)比较差异均无显著意义(p0.05)。由此确定在研究各剂量含药血浆在对SGC-7901细胞株增殖影响时,各含药血浆的加入浓度均取10%。胃复方含药血浆能抑制SGC-7901细胞增殖,作用胃癌SGC-7901细胞株24小时后,胃复方空白组、低剂量组、中剂量组、高剂量组OD值分别为0.697±0.040、0.654±0.032、0.548±0.048、0.036±0.029;48小时后OD值分别为1.233±0.081、1.131±0.040、0.856±0.055、0.413±0.065;72小时后OD值分别为1.736±0.026、1.362±0.013、0.748±0.024、0.326±0.020,差异均有统计学意义(p0.05)。胃复方含药血浆在作用胃癌SGC-7901细胞48小时后,PPARγ基因随着浓度的增高表达上调,低剂量、中剂量、高剂量胃复方含药血浆的相对表达量分别是空白血浆的(41.1172±1.9615)倍、(4448.5509±4.7522)倍、(14893.2846±1.0381)倍,与空白组相比差异有统计学意义(p0.05)。结论:1、胃复方含药血浆随药物浓度的增加和作用时间的延长对胃癌SGC-7901细胞的增殖抑制作用逐渐增加,呈时间和浓度依赖性。提示胃复方对胃癌增殖有抑制作用。2、胃复方含药血浆干预后,SGC-7901细胞PPARγ表达水平呈剂量依赖性增加,提示胃复方含药血浆可能通过上调PPARγ基因表达的途径来抑制胃癌SGC-7901细胞增殖。
[Abstract]:Objective: to observe the effect of gastric compound drug containing plasma on proliferation of gastric cancer SGC-7901 cell line and on PPAR 纬 (peroxidase proliferation-activated receptor 纬). To explore the possible mechanism of the effect of gastric compound plasma containing drugs on the proliferation of gastric cancer cells. Methods: blank group, low dose group and middle dose group were used in gastric compound plasma containing medicine (final concentration was 10). The high dose group was treated with gastric compound SGC-7901 cell line for 24 h and 48 h. After 72 hours, the inhibition rate of proliferation was detected by CCK-8 assay. 48 hours after different concentrations of compound plasma were treated with gastric cancer SGC-7901 cell line. The expression of PPAR 纬 in gastric cancer SGC-7901 cell line was detected by fluorescence quantitative assay. Results: the low dose gastric compound plasma ICSP 50 was used to detect the expression of PPAR 纬 in gastric cancer SGC-7901 cell line. It was 11.1% 卤2.0%. The ICSP 50 of medium dose gastric compound plasma was 13.5% 卤3.1%. The plasma ICS 50 of high dose gastric compound was 12.3% 卤1.5.There was no significant difference between the two groups (P 0.05). It was determined that the effects of different doses of plasma containing drugs on the proliferation of SGC-7901 cell line were studied. The concentration of each drug plasma was 10. The gastric compound plasma could inhibit the proliferation of SGC-7901 cells. 24 hours after the action of gastric cancer SGC-7901 cell line, the stomach compound blank group. The OD values of low dose group, middle dose group and high dose group were 0.697 卤0.040 ~ 0.654 卤0.032 ~ 0.548 卤0.048 卤0.048 卤0.036 卤0.029 respectively. After 48 hours, the OD values were 1.233 卤0.081, 1.131 卤0.040, 0.856 卤0.055, 0.413 卤0.065, respectively. After 72 hours, the OD values were 1.736 卤0.026, 1.362 卤0.013, 0.748 卤0.024 and 0.326 卤0.020, respectively. The difference was statistically significant (P 0.05). The expression of PPAR- 纬 gene in gastric cancer SGC-7901 cells was up-regulated with the increase of concentration, and the dose was low. The relative expression of medium dose, high dose gastric compound plasma was 41.1172 卤1.9615 times of blank plasma, 4448.5509 卤4.7522 times of blank plasma respectively. It was 14893.2846 卤1.0381fold, which was significantly different from that of the blank group (P 0.050.Conclusion 1). With the increase of drug concentration and the prolongation of the time of action, the inhibition of SGC-7901 cell proliferation was gradually increased. The results indicated that gastric compound had inhibitory effect on gastric cancer proliferation, and the expression of PPAR 纬 in SGC-7901 cells was increased in a dose-dependent manner after plasma intervention. The results suggest that the plasma containing medicine may inhibit the proliferation of gastric cancer SGC-7901 cells by upregulating the expression of PPAR 纬 gene.
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R285

【参考文献】